Dr. Arjun Gupta and colleagues published a paper today entitled, ‘Use of Bone Modifying Agents Among Medicare Beneficiaries with Multiple Myeloma,’ in JAMA Oncology. In this video, Dr. Gupta reviews the paper and explains how the use of denosumab has skyrocketed in patients with multiple myeloma since its FDA approval in January 2018.
 
VN:F [1.9.17_1161]
Rating: 5.0/5 (1 vote cast)

Study Explores Shift in Bone Medication for Multiple Myeloma, 5.0 out of 5 based on 1 rating

Share This Post